Singapore markets closed

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.4670-0.0438 (-8.57%)
At close: 04:00PM EST
0.4700 +0.00 (+0.64%)
After hours: 07:33PM EST

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive
Norwood, MA 02062
United States
617 963 0100
https://www.corbuspharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees76

Key executives

NameTitlePayExercisedYear born
Dr. Yuval CohenCEO & Director827.32kN/A1975
Mr. Sean F. Moran CPA, M.B.A., CPA, MBAChief Financial Officer528kN/A1958
Mr. Craig Stuart Millian M.B.A.Chief Operating Officer.N/AN/A1968
Dr. Rachael Brake Ph.D.Chief Scientific OfficerN/AN/AN/A
Ted JenkinsSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Lindsey SmithHead of Corp. Communications & Patient AdvocacyN/AN/AN/A
Ms. Christina BertschHead of HRN/AN/AN/A
Scott ConstantineSr. Director & Head of Clinical OperationsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corporate governance

Corbus Pharmaceuticals Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.